• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NQ:AZN)

    67.57 +0.27 (+0.40%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,207,519
    Open 68.04
    Bid (Size) 67.40 (10)
    Ask (Size) 67.75 (10)
    Prev. Close 67.30
    Today's Range 67.52 - 68.63
    52wk Range 61.24 - 87.67
    Shares Outstanding N/A
    Dividend Yield 3.11%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens
    The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and maintenance therapy in the trial. 
    Via Stocktwits
    IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
    From AstraZeneca
    Via Business Wire

    Performance

    YTD
    +2.6%
    +2.6%
    1 Month
    +4.1%
    +4.1%
    3 Month
    -6.6%
    -6.6%
    6 Month
    +4.5%
    +4.5%
    1 Year
    -12.2%
    -12.2%

    More News

    Read More
    Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
    Via Benzinga
    Topics ETFs Government
    Exposures Political
    What Does the Market Think About AstraZeneca?
    Via Benzinga
    Earnings Scheduled For April 29, 2025
    Via Benzinga
    Tempus AI Stock: Time to Double Down or Cut and Run?
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
    From AstraZeneca
    Via Business Wire
    Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment Dips
    Via Stocktwits
    AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
    Via Benzinga
    Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive
    Via Stocktwits
    BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
    From AstraZeneca
    Via Business Wire
    AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty
    Via Benzinga
    AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
    Via Investor's Business Daily
    Topics Earnings Government
    Exposures Financial Political Product Safety
    NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
    Via Benzinga
    AstraZeneca's Q1 2025 Financial Results
    From AstraZeneca
    Via Business Wire
    Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
    Via Talk Markets
    Topics ETFs Stocks / Equities
    Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
    Via MarketBeat
    AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
    Via Benzinga
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
    From AstraZeneca
    Via Business Wire
    2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
    Via The Motley Fool
    Topics Government World Trade
    Exposures Political Tariff

    Frequently Asked Questions

    Is AstraZeneca PLC - American Depositary Shares publicly traded?
    Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
    What exchange does AstraZeneca PLC - American Depositary Shares trade on?
    AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
    The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
    What is the current price of AstraZeneca PLC - American Depositary Shares?
    The current price of AstraZeneca PLC - American Depositary Shares is 67.57
    When was AstraZeneca PLC - American Depositary Shares last traded?
    The last trade of AstraZeneca PLC - American Depositary Shares was at 05/09/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.